LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
Linda Chapdeleine Mekue Mouafo 1 , 2
Hélène Péré 2 , 3
Angélique Ndjoyi-Mbiguino 4
Donato Koyalta 5
Jean De Dieu Longo 6
François-Xavier Mbopi-Kéou 7
Coumba Toure Kane 8
Laurent Bélec, *
, 2 , 3
Authors Info & Affiliations
, 2 , 3
Authors Info & Affiliations
Abstract
Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq® HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq® sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq® HIV-1 genotyping system for non-B subtypes HIV-1.
Keywords: Central Africa, non-B subtypes HIV-1, VirosSeq®HIV-1 Genotyping System v2.0.
